COMP <GO>
CME vs JPM // 10Y YIELD & FRED MACRO BETA
CME Group Inc. (NASDAQ) VS. JPMorgan Chase & Co. (NYSE) • 15-METRIC TALLY: CME 8
— JPM 6
▲ 10Y YIELD & FRED MACRO BETA LEADER: CME
LAST: $303.14 (+2.27%) • MKT CAP: $106.10B
macro-sensitivity
1.01
LAST: $337.04 (-1.90%) • MKT CAP: $895.92B
macro-sensitivity
1.00
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CME VS. JPM)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CME | JPM | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 3.50% | 17.37% | -13.87 | JPM | /roic <GO> |
| EV/EBITDA & P/E Valuation | 40.2x | 9.7x | +30.53 | JPM | /valuation <GO> |
| Free Cash Flow Yield | 3.95% | -18.14% | +22.09 | CME | /fcf-yield <GO> |
| Operating Margin | 64.90% | 42.07% | +22.83 | CME | /operating-margins <GO> |
| Net Profit Margin | 62.50% | 32.63% | +29.87 | CME | /net-margins <GO> |
| Revenue Growth (YoY) | 6.40% | 13.53% | -7.13 | JPM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 3.71% | 1.96% | +1.75 | CME | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.55 | 0.37 | +0.18 | CME | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 2/9 | +6.00 | CME | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 4.84% | +2.06 | JPM | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 65.4 | 49.0 | +16.35 | CME | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.01 | 1.00 | +0.01 | CME | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.3x | 13.6x | +10.73 | JPM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $106.10B | $895.92B | -$789.82B | JPM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CME REV | JPM REV | CME GROSS % | JPM GROSS % | CME FCF | JPM FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $6.52B | $182.45B | 44.0% | — | $4.19B | -$147.78B |
| FY 2024 | $6.13B | $177.56B | 44.0% | — | $3.60B | -$42.01B |
| FY 2023 | $5.58B | $158.10B | 44.0% | — | $3.20B | $12.97B |
| FY 2022 | — | $128.69B | — | — | — | $107.12B |
| FY 2021 | — | $121.65B | — | — | — | $78.08B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CME // BETA 1.01
JPM // BETA 1.00